Windtree Therapeutics, Inc. Current Part of Debt

Current Part of Debt of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending June 29, 2020 was $5.71 Million (a 716.29% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt decreased by -26.57%
  • Annual Current Part of Debt for 2019 was $161 Thousand (a -97.98% decrease from previous year)
  • Annual Current Part of Debt for 2018 was $7.97 Million (a 12761.29% increase from previous year)
  • Annual Current Part of Debt for 2014 was $62 Thousand (a -15.07% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Windtree Therapeutics, Inc.

Most recent Current Part of Debtof WINT including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $5.71 $0.7
2019 $0.16 $7.78 $8.05 $7.47 $0.16
2018 $7.97 $5.25 $2.5 $2.5 $7.97
2017 $15.1 $12.5 $12.5
2015 $0.02 $0.04
2014 $0.06 $0.08 $0.08 $0.07 $0.06
2013 $0.07 $0.07 $0.07 $0.07
2012 $0.07 $0.07 $0.07 $0.07 $0.07
2011 $0.07 $0.07 $0.09 $0.12 $0.07
2010 $0.14 $0.2 $4.33 $11.02 $0.14

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.